Press Releases

Press Releases
Date Title and Summary View
Apr 17, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www....
Apr 9, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Friday, May 04, 2018 at 9 a.m. ET to discuss first quarter 2018 financial and operational results. The first quarter results will include the financial and operational results of Juno ...
Apr 2, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that Scott A. Smith, President and Chief Operating Officer, is leaving the company effective immediately. His primary responsibilities will be assumed by Chairman and Chief Executive Officer Mark J. Alles. ...
Mar 28, 2018 - bluebird and Celgene will share 50% of U.S. costs and profits - - bluebird to receive milestones and royalties on ex-U.S. sales - CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today annou...
Mar 6, 2018 Advances Strategy to Become a Leader in Global Cellular Immunotherapy Immediately Adds Late-Stage Therapy JCAR017, an Expected Growth Driver From 2020 and Beyond with Potential Global Peak Sales of Approximately $3B SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation...
Mar 5, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, Inc. at a price of $87.00 per share, net to the seller in cash, without interest and less required withholding taxes, ...
Feb 27, 2018 Conference call scheduled for today at 5:30 p.m. ET SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ...
Feb 27, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Feb 21, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by Celgene's wholly owned subsidiary, Blue Magpie Corporation, for all ...
Feb 17, 2018 RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12 Significant improvements in key secondary endpoints, including oral ulcer pain, overall disease activity and quality of life Data presented at t...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase